| 卵巢透明细胞癌基因突变特征及相关靶向和免疫治疗研究进展 |
| |
| 引用本文： | 马婧兰,殷 霞. 卵巢透明细胞癌基因突变特征及相关靶向和免疫治疗研究进展[J]. 现代肿瘤医学, 2023, 0(9): 1756-1760. DOI: 10.3969/j.issn.1672-4992.2023.09.033 |
| |
| 作者姓名： | 马婧兰 殷 霞 |
| |
| 作者单位： | 上海交通大学医学院附属仁济医院妇产科，上海市妇科肿瘤重点实验室，上海 200127 |
| |
| 基金项目： | National Natural Science Foundation of China（No.82173077）;国家自然科学基金面上项目(编号:82173077);北京康华中西医发展基金会医学科研项目(编号:KH-2021-LLZX-018);上海申康医院发展中心临床创新研发项目(编号:SHDC2020CR3057B);上海交通大学医工交叉项目(编号:YG2021GD02) |
| |
| 摘 要： | 卵巢透明细胞癌(ovarian clear cell carcinoma, OCCC)是上皮性卵巢癌中特殊的组织病理学类型，对铂类为基础的化疗表现出原发性耐药，预后极差。深入研究OCCC独特的分子突变特征有助于在靶向和免疫治疗方面获得突破，对提高治疗效果和改善患者预后有重要意义。本文对近年来OCCC靶向治疗相关基因突变特征(例如ARID1、PI3K/AKT/mTOR、APOBEC等)进展进行全面综述和深入阐述。
|
| 关 键 词： | 卵巢透明细胞癌 基因突变 靶向治疗 免疫治疗 |
Research progress on gene mutation characteristics of ovarian clear cell carcinoma and related targeting and immunotherapy |
| |
| MA Jinglan,YIN Xia. Research progress on gene mutation characteristics of ovarian clear cell carcinoma and related targeting and immunotherapy[J]. Journal of Modern Oncology, 2023, 0(9): 1756-1760. DOI: 10.3969/j.issn.1672-4992.2023.09.033 |
| |
| Authors: | MA Jinglan YIN Xia |
| |
| Affiliation: | Department of Obstetrics and Gynecology，Renji Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai Key Laboratory of Gynecologic Oncology，Shanghai 200127，China. |
| |
| Abstract: | Ovarian clear cell carcinoma(OCCC) is a distinct histological subtype of epithelial ovarian cancer(EOC) with poor prognosis due to the primary platinum chemo-resistance.Investigation of its unique molecular characteristics is crucial to figure out effective therapeutic targets，which is important in improving clinical efficacy and prognosis for patients.We comprehensively reviews the recent progress of treatment related mutation characteristics including ARID1,PI3K/AKT/mTOR,APOBEC. |
| |
| Keywords: | ovarian clear cell carcinoma gene mutation targeted therapy immunotherapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
